Phase 1 Breast Cancer Trial, Recruiting (NCT06999798)

Phase 1 Breast Cancer Trial, Recruiting NCT06999798 Sponsor: Mayo Clinic Condition: Breast Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT06999798 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Breast Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People aged 18 or older who have breast cancer and have had a biopsy confirming that cancer has spread to at least one lymph node in the armpit area
People whose surgery will be performed by one of the listed surgeons in the Division of Breast and Melanoma Surgical Oncology at the trial site (Dr. Judy Boughey, Dr. Amy Degnim, Dr. Tina Hieken, Dr. Jeffrey Johnson, Dr. Mary Mrdutt, or Dr. Shon Black)
People who are able to understand what the study involves and are willing to follow the study procedures for its full duration
No contraception is required as part of this trial

Who may not be able to join:

People who are currently pregnant
People with current drug or alcohol use or dependence that the trial team believes could affect their ability to follow the study requirements
People who are currently participating in, or have recently participated in, another clinical trial involving a similar procedure or intervention (confirm with trial site for the specific timeframe)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 21 July 2026

Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Christine U. Lee, MD, PhD, Mayo Clinic in Rochester

Phone: 855-776-0015

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT06999798

Sponsor: Mayo Clinic

Phase: Phase 1

Status: Recruiting

Condition: Breast Cancer

Trial contact: 855-776-0015

More information: https://clinicaltrials.gov/study/NCT06999798

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People aged 18 or older who have breast cancer and have had a biopsy confirming that cancer has spread to at least one lymph node in the armpit area
People whose surgery will be performed by one of the listed surgeons in the Division of Breast and Melanoma Surgical Oncology at the trial site (Dr. Judy Boughey, Dr. Amy Degnim, Dr. Tina Hieken, Dr. Jeffrey Johnson, Dr. Mary Mrdutt, or Dr. Shon Black)
People who are able to understand what the study involves and are willing to follow the study procedures for its full duration
No contraception is required as part of this trial

Who may not be able to join:

People who are currently pregnant
People with current drug or alcohol use or dependence that the trial team believes could affect their ability to follow the study requirements
People who are currently participating in, or have recently participated in, another clinical trial involving a similar procedure or intervention (confirm with trial site for the specific timeframe)

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 21 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 1

Sponsor

Mayo Clinic

Registry

ClinicalTrials.gov

Start date

29 August 2025

Est. completion

30 July 2026

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Conspicuity of the optimized Mayo-developed twinkling marker; Migration of the optimized Mayo-developed twinkling marker

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov